ESPR (esperion.com) Enterprise Value-to-Revenue Coefficient

Esperion Therapeutics (ESPR) aims to capture the statin market with its drug Nexletol, expanding its global presence. Demand for cardiology treatments remains stable and independent of economic conditions. On GURU.Markets, the company's current enterprise value-to-revenue ratio visualizes the business valuation excluding debt, where 2883.94 captures the magnitude of this parameter. Consistent drug prescriptions create a reliable cash flow, ensuring long-term financial health.
Esperion Therapeutics, Inc. - analytical breakdowns and key metrics (ESPR)

For Esperion Therapeutics (ESPR), which has created a closed-loop non-statin therapy, assessing operational efficiency is critical. This indicator compares market capitalization and net debt against sales volume. By analyzing the enterprise value-to-revenue ratio, an investor determines the real price per unit of income excluding leverage. This allows for the elimination of debt distortions when valuing biopharmaceutical assets. Low enterprise value-to-revenue ratios signal that the business is undervalued.